Your session is about to expire
← Back to Search
Study of Kidney Tumors in Younger Patients
N/A
Recruiting
Led By Elizabeth A Mullen
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years from study enrollment
Awards & highlights
No Placebo-Only Group
Summary
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Eligible Conditions
- Angiolipoma
- Wilms Tumor
- Kidney Cancer
- Kidney Tumors
- Infantile renal fibrosarcoma
- Renal Tumor of Infancy
- Metanephric Stromal Tumor
- Kidney Cell Carcinoma
- Rhabdoid Tumor
- Congenital Mesoblastic Nephroma
- Cystic Nephroma
- Clear Cell Sarcoma of the Kidney
- Nephroblastoma
- Diffuse Hyperplastic Perilobar Nephroblastomatosis
- Extrarenal Rhabdoid Tumor
- Kidney Carcinoma
- Kidney Oncocytoma
- Metanephric Adenofibroma
- Metanephric Adenoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years from study enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years from study enrollment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Event-free survival
Overall survival
Secondary study objectives
Loss of heterozygosity (LOH testing discontinued as of April 2014)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Ancillary-correlative (renal tumor classification, biology)Experimental Treatment2 Interventions
Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)
Find a Location
Who is running the clinical trial?
Children's Oncology GroupLead Sponsor
460 Previous Clinical Trials
231,998 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,941 Previous Clinical Trials
41,015,400 Total Patients Enrolled
Elizabeth A MullenPrincipal InvestigatorChildren's Oncology Group
2 Previous Clinical Trials
2,464 Total Patients Enrolled